• HPR13 Acceptance of Clinical Studies Conducted in Nonus Settings by the FDA Based on the Analysis of Selected Novel Drug Approvals

    Dec 1, 2025, 00:00

  • EE669 Spillover Effect in Health Utility Values: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR263 Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • EE10 A Cost-Effectiveness Analysis of First-Line Therapies for Microsatellite-Instability-High (MSI-H) or Mismatch-Repair-Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (mCRC) in France

    Dec 1, 2025, 00:00

  • EE589 Modeling the Healthcare Burden of Oral Corticosteroid Use in Mexico

    Dec 1, 2025, 00:00

  • HTA302 Statistical Analysis of Health Technology Assessment Outcomes in Oncology: An Analysis of Key Clinical Value Drivers in Germany and France

    Dec 1, 2025, 00:00

  • HPR88 External Reference Pricing (ERP) Availability vs. Reimbursement Timelines in Poland and Other European Countries: The Analysis of EURIPID Database

    Dec 1, 2025, 00:00

  • PCR226 The EB Insights Study: The Impact of Epidermolysis Bullosa on Carer Health-Related Quality of Life

    Dec 1, 2025, 00:00

  • EE40 Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts

    Dec 1, 2025, 00:00

  • EE600 Optimizing Colorectal Cancer Screening in the Czech Republic: Cost-Effectiveness of Lowering the Starting Age to 45 and Introducing an Upper Limit

    Dec 1, 2025, 00:00

  • EPH82 Epidemiology of Diabetes Mellitus in Pregnancy in Hungary: Trends and Future Projections

    Dec 1, 2025, 00:00

  • MT17 From Anxiety to Hope: Understanding the Adoption of AI Counseling Tools for Anxiety Management

    Dec 1, 2025, 00:00

  • RWD32 Characterizing Comorbidities and Co-Occurring Conditions in Adults with Generalized Anxiety Disorder in the United States

    Dec 1, 2025, 00:00

  • EE121 Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study

    Dec 1, 2025, 00:00

  • EE574 Measures for Integrating Carbon Footprints Into Economic Evaluations: A Targeted Review of Environmental and Economic Metrics

    Dec 1, 2025, 00:00

  • EE62 Assessing the Health-Related Quality of Life and Economic Burden of Dry Eye Disease in Thailand: A Multi-Center Study on Patient-Reported Outcomes

    Dec 1, 2025, 00:00

  • MSR190 Structured Expert Elicitation for Survival Outcomes: Insights From NICE Technical Support Document 26

    Dec 1, 2025, 00:00

  • HPR60 Diverging Impacts of Evergreening and Biosimilars on Trastuzumab Utilization and Costs in South Korea: Implications for Sustainable Access and Market Competition

    Dec 1, 2025, 00:00

  • MT9 Clinical Outcomes of Early Diagnosis of Infections of Sterile Body Fluids: A Living Systematic Review and Meta Analysis

    Dec 1, 2025, 00:00

  • EE517 Healthcare Resource Utilization for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan

    Dec 1, 2025, 00:00

  • EE684 Technical Validation of Health Economic Models: Is There a Gold Standard? Assessment and Refinement of Current Checklist Tools

    Dec 1, 2025, 00:00

  • EE349 Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China

    Dec 1, 2025, 00:00

  • EPH216 Social Inequality in the Uptake of Varicella Vaccination: A Danish Nationwide Observational Study

    Dec 1, 2025, 00:00

  • EE701 The Economic Burden of Moderate and Severe Anxiety and Depression Symptoms in Saudi Arabia

    Dec 1, 2025, 00:00

  • EE707 The Economic Value of Self-Administered Subcutaneous Immunoglobulin G (SCIg) in Canada: A Scoping Review

    Dec 1, 2025, 00:00

  • EE176 Cost Of Adverse Events Associates With the Management of Invasive Mold Disease With Isavuconazole Compared With Voriconazole in Spain

    Dec 1, 2025, 00:00

  • PCR190 Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan

    Dec 1, 2025, 00:00

  • MSR39 Assessing Bias in LLM-Extracted Real-World Data: A Health Equity Analysis of Access to Care and Outcomes in Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • RWD99 Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE67 Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection

    Dec 1, 2025, 00:00

  • PCR81 Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada

    Dec 1, 2025, 00:00

  • HTA112 Digital Health Technologies Assessment Based on Patient-Reported Outcome Measures (PROMs): Virtual Reality (VR) in the Treatment of Specific Phobias

    Dec 1, 2025, 00:00

  • HTA315 The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)

    Dec 1, 2025, 00:00

  • EPH81 Epidemiology of Breast Cancer in France

    Dec 1, 2025, 00:00

  • EE638 Real-World Healthcare Resource Utilization in Individuals With Phenylketonuria: A Retrospective Observational Study in the United States

    Dec 1, 2025, 00:00

  • CO252 Tocilizumab vs. Sarilumab Among Adults Hospitalized Due to COVID-19: A Federated Comparative Effectiveness Study Across England and Scotland Under the Target Trial Emulation Framework

    Dec 1, 2025, 00:00

  • HTA43 Artificial Intelligence-Based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA)

    Dec 1, 2025, 00:00

  • EE8 A Cost per Responder Analysis of Lipid-Lowering Therapies in Patients With Established Atherosclerotic Cardiovascular Disease in Italy

    Dec 1, 2025, 00:00

  • EE368 Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HPR171 Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers

    Dec 1, 2025, 00:00

  • HTA309 Systematic Review of Value Assessment Frameworks for Digital Health Interventions: Toward a Multidimensional Evaluation Approach

    Dec 1, 2025, 00:00

  • HPR95 Financial Impact of EU MDR Complian A Cost-Mapping Assessment for Manufacturers

    Dec 1, 2025, 00:00

  • MSR51 Can an Ensemble Machine-Learning Approach Outperform Traditional Models While Enhancing Accuracy, Fairness, and Interpretability in Clinical Risk Prediction?

    Dec 1, 2025, 00:00

  • SA50 How Much Time Does Artificial Intelligence Really Save in Evidence Synthesis? A Systematic Literature Review

    Dec 1, 2025, 00:00

  • SA103 What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks

    Dec 1, 2025, 00:00

  • RWD161 Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK

    Dec 1, 2025, 00:00

  • HSD10 Assessing the Quality and Determinants of Referrals From General Practitioners (Primary Care Physicians for Adults) to Specialist Physicians in the Cyprus Healthcare System

    Dec 1, 2025, 00:00

  • CO170 Network Meta-Analysis for an Efficacy Assessment of Avelumab Axitinib in the First-Line Treatment of International Metastatic RCC Database Consortium (IMDC) Favorable Risk Patients With Advanced Renal Cell Carcinoma (ARCC)

    Dec 1, 2025, 00:00

  • MSR176 Q-Squared as a Mapping Model Performance Metric in Gastrointestinal Disease

    Dec 1, 2025, 00:00

  • MSR220 What About a Latent Cure Model? Assessing Cure Models’ Performance in Pediatric Acute Lymphoblastic Leukemia Treated With Tisagenlecleucel

    Dec 1, 2025, 00:00

  • RWD25 Best Practices Framework for Real-World Data (RWD) in Regulatory Submissions

    Dec 1, 2025, 00:00

  • PT25 Systems-Level Modeling Approaches for Complex Health Technologies: A Systematic Review

    Dec 1, 2025, 00:00

  • HSD14 Biologic Treatment Patterns and Phenotyping in Severe Uncontrolled Asthma: A Multinational Study

    Dec 1, 2025, 00:00

  • HPR215 The Value of Medical Spending in China, 1991-2019

    Dec 1, 2025, 00:00

  • HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions

    Dec 1, 2025, 00:00

  • EPH27 Beyond the Guidelines: Exploring the Characteristics and Comorbidity Profiles of Adults With Pneumococcal Disease in England Not Covered by Current Pneumococcal Vaccination Criteria

    Dec 1, 2025, 00:00

  • RWD59 Development and Evaluation of a Proactive Monitoring Model for Adverse Drug Events in Patients With Pulmonary Arterial Hypertension Based on the Delphi and Real-World Data

    Dec 1, 2025, 00:00

  • HTA114 Diverging Health Technology Assessment Outcomes Between SMC and HAS: A Focus on the Role of Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • RWD29 Characteristics of Real-World Data Landscape in Italy: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA363 What Generalized Cost-Effectiveness Analysis (GCEA) Reveals About the Applicability of Foreign Reference Pricing in Medicare Price Negotiation in the US

    Dec 1, 2025, 00:00

  • EPH233 The Epidemiology Burden and Management of Chronic Hand Eczema in Adolescents: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • RWD186 Trends of Prescriptions for Medical Technologies Not Covered by the Colombian Health Benefits Package Between 2020 and 2024: A Descriptive Study

    Dec 1, 2025, 00:00

  • EPH60 Development of a Markov Model-Based Visualization Tool of Regional HPV Vaccination Coverage Rates Over Time in Austria: Combining Data From Pharmaceutical Industry and Healthcare Data Including National Vaccination Registry

    Dec 1, 2025, 00:00

  • EE568 Long-Term Economic Impact of Nonpersistence to Disease-Modifying Therapies in a Cohort of German Patients With Multiple Sclerosis

    Dec 1, 2025, 00:00

  • HPR84 Evolving Trends in US Healthcare Policy: Perspectives From US Formulary Decision Makers

    Dec 1, 2025, 00:00

  • EPH237 The Health Impact of Pembrolizumab for the First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC) That Expresses High Levels of PD-L1 in Türkiye

    Dec 1, 2025, 00:00

  • HTA207 Integrating Patient Perspectives Into Drug Reimbursement Decisions: Insights From Taiwan’s Deliberative HTA Process

    Dec 1, 2025, 00:00

  • EE495 Health Utilities Among Patients With Chronic Rhinosinusitis With Nasal Polyps: An Exploratory Analysis From the WAYPOINT Trial

    Dec 1, 2025, 00:00

  • CO184 Predictors of Postoperative Complications Following Cytoreductive Surgery With HIPEC: A Real-World Analysis of 493 Patients in Québec

    Dec 1, 2025, 00:00

  • HSD11 Assessing the Quality of Hemophilia Care: How Suitable Are Patient-Centered Outcomes to Compare Hospital Performance?

    Dec 1, 2025, 00:00

  • EE730 Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK

    Dec 1, 2025, 00:00

  • HPR135 Managed Reimbursement of Continuous Glucose Monitoring Sensors in Ireland: Year One Review

    Dec 1, 2025, 00:00

  • EE4 A Budget Impact Model of Switching From Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring for Individuals With Type 2 Diabetes Mellitus Receiving Basal Insulin in Italy

    Dec 1, 2025, 00:00

  • SA72 Network Meta-Analysis of Survival Outcomes in the First-Line Treatment of Unresectable or Metastatic Melanoma: Scoping Review of Methodology

    Dec 1, 2025, 00:00

  • EE147 Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?

    Dec 1, 2025, 00:00

  • CO226 Systematic Literature Review (SLR) of First-Line (1L) Treatments of Patients With Advanced or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma (GEA)

    Dec 1, 2025, 00:00

  • EE200 Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective

    Dec 1, 2025, 00:00

  • Patient-Reported Outcomes Now and Into the Future: Multistakeholder Perspectives on Optimizing the Use of Patient-Reported Outcome Evidence in Decision Making Across the US Healthcare Continuum

    Dec 1, 2025, 00:00

  • MT38 Standardizing Healthtech Evidence to Meet NICE Expectations

    Dec 1, 2025, 00:00

  • EPH29 Budget Impact of an Organized Cervical Cancer Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • PCR153 Meaningful Within-Patient Change of the IWQOL-Lite-CT Physical Function Composite in Adults With Obesity

    Dec 1, 2025, 00:00

  • EE614 Preventing Stunting Through Early Nutritional Intervention: Effectiveness and Economic Evaluation in Children With Weight Faltering

    Dec 1, 2025, 00:00

  • EE351 Economic and Social Burden of Pulmonary Hypertension in Italy

    Dec 1, 2025, 00:00

  • MSR172 Predictive Algorithms in HTA: What Factors Influence Decision Making in NICE, SMC, and NCPE?

    Dec 1, 2025, 00:00

  • SA34 Direct Healthcare Costs (HCCs) Inequalities Associated With Myasthenia Gravis (MG) in Hungary: Claims Database Analysis

    Dec 1, 2025, 00:00

  • EE712 The Impact of Burosumab on the Clinical and Economic Burden of X-Linked Hypophosphatemia in Adult Patients in France

    Dec 1, 2025, 00:00

  • RWD146 Real-World Adherence to Nonhormonal Therapies for Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HPR7 A Decade of Change in Turkish Healthcare Utilization: Hospital Admission Trends 2015-2024

    Dec 1, 2025, 00:00

  • The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs

    Dec 1, 2025, 00:00

  • EE305 Cost-Utility Analysis of Multiplex Cell Culture Technology for Predicting Carboplatin Plus Paclitaxel-Induced Side Effects in Cancer Care

    Dec 1, 2025, 00:00

  • SA69 Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review

    Dec 1, 2025, 00:00

  • CO209 Real-World Treatment Patterns and Outcomes in First-Line Small-Cell Lung Cancer (SCLC) in France

    Dec 1, 2025, 00:00

  • EPH59 Development and Validation of a Case Identification Algorithm for Hand Trauma Patients Using Health Administrative Data and the Epidemiology of Hand Trauma in a Universal Healthcare System

    Dec 1, 2025, 00:00

  • PCR207 Real-World Socioeconomic Burden and Health-Related Quality of Life (HRQoL) for Patients Living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the UK: Results From an Online Patient Survey

    Dec 1, 2025, 00:00

  • CO68 Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings

    Dec 1, 2025, 00:00

  • CO187 Preventing Bleeds in Pediatric Patients With Hemophilia A: Which Factor Replacement Therapy Offers the Best Protection and at What Cost?

    Dec 1, 2025, 00:00

  • EE421 Estimating Life-Years and QALYs Gained From Tumor Treating Fields in Newly Diagnosed Glioblastoma: A US-Based Real-World Survival-Based Model

    Dec 1, 2025, 00:00

  • PT33 Trends in Reimbursement Agreements for Innovative Orphan and Oncological Medicines in Spain 2020-2025

    Dec 1, 2025, 00:00

  • PCR113 Health-Related Quality of Life Among People With Arthritis in Ireland

    Dec 1, 2025, 00:00

  • CO228 Systematic Literature Review of Artificial Intelligence-Based Models Predicting COPD Exacerbations

    Dec 1, 2025, 00:00

  • HTA271 Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis

    Dec 1, 2025, 00:00

  • PCR174 Patient Perspectives on Mild-Moderate Infection Burden in Multiple Myeloma and Chronic Lymphocytic/Small Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PCR34 Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries

    Dec 1, 2025, 00:00

  • HPR156 Payer and HTA Evaluation Criteria and Considerations for Coverage and Reimbursement of Patient Self-Monitoring Technology

    Dec 1, 2025, 00:00

  • SA37 Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review

    Dec 1, 2025, 00:00

  • RWD57 Design Operating Characteristics in a Noninterventional Study Framework

    Dec 1, 2025, 00:00

  • HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?

    Dec 1, 2025, 00:00

  • PT21 Can Generative AI Deliver Patient-Friendly Summaries? A Case Study Using NICE Guidance for Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • CO80 Early Life Hypoglycemia and Neurological Sequalae in Children With Congenital Hyperinsulinism

    Dec 1, 2025, 00:00

  • HTA287 Reimbursement Trends for GLP-1s and Emerging Antiobesity Drugs Across Seven Global Markets

    Dec 1, 2025, 00:00

  • EE426 Estimating the Economic Burden of DLBCL: Developing and Testing a Cost of Disease Model

    Dec 1, 2025, 00:00

  • EPH132 Identifying Risk Factors Associated With Meningioma: A Systematic Review

    Dec 1, 2025, 00:00

  • EE56 Assessing Productivity in Health Technology Assessment: A Comparative Review of Human Capital and Friction Cost Approaches in Europe

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • PCR127 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Myelodysplastic Syndromes (MDS)

    Dec 1, 2025, 00:00

  • EE557 Integrating Environmental Sustainability Into Cost-Effectiveness Analysis and Value Demonstration: A Multidimensional Framework

    Dec 1, 2025, 00:00

  • HTA351 Use of the ESMO-Magnitude of Clinical Benefit Scale to Guide HTA Recommendations on Coverage and Reimbursement for Cancer Medicines in Ireland: A Retrospective Analysis

    Dec 1, 2025, 00:00

  • HPR17 Advancing INN-Based Prescribing in Saudi Arabia’s Private Sector: Implications for Biologics and Biosimilars Utilization Under CHI Oversight

    Dec 1, 2025, 00:00

  • EE437 Evaluating the Cost-Effectiveness of High-Dose Influenza Vaccination for Adults Aged 60 Years and Older in Austria

    Dec 1, 2025, 00:00

  • HTA171 Health Equity Considerations in Economic Evaluation: Comparative Acceptability and Application Across European HTA Bodies

    Dec 1, 2025, 00:00

  • RWD61 Development and Implementation of a Health and Well-being Index to Inform Risk Management and Patient Engagement in a Colombian Health Insurance Plan

    Dec 1, 2025, 00:00

  • EE720 The Public Health and Economic Effects of Various RSV Vaccination Strategies With RSVpreF Among Adults in France

    Dec 1, 2025, 00:00

  • HTA199 Increased Trends of Self-Optimized Submissions to NICE

    Dec 1, 2025, 00:00

  • CO124 Gaps in Cancer Screening Uptake in Ireland: Trends, Barriers and Policy Implications

    Dec 1, 2025, 00:00

  • EPH275 Urinary Dysfunction Management in Multiple Sclerosis: A Nationwide Real-Life Analysis From the French SNDS Database

    Dec 1, 2025, 00:00

  • HSD103 Standardizing Point-of-Care mRNA-Based Gene Therapy Production in Europe: A Cost and Capacity Analysis of the Nanospresso Platform

    Dec 1, 2025, 00:00

  • EE533 Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Hospitalization Burden in Norway

    Dec 1, 2025, 00:00

  • EE488 Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France

    Dec 1, 2025, 00:00

  • EE758 Work Complexity in Adults With Phenylketonuria in Sweden in 2020

    Dec 1, 2025, 00:00

  • EPH250 The Longevity Conundrum: Population Aging in the UK

    Dec 1, 2025, 00:00

  • RWD34 Clinical Outcomes and Economic Burden of Acute Lower Respiratory Tract Infection-Related Hospitalizations Among Adults in the United States Post COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • HTA152 From GVD to HTA: Preparing for Success in the EU JCA Era With GenAI-Enhanced Efficiency

    Dec 1, 2025, 00:00

  • CO116 Expert Consensus on the Clinical and Economic Value of Advanced Wound-Care Products in Mexico: Results From a Delphi Panel

    Dec 1, 2025, 00:00

  • RWD88 Gender Inequalities in Aortic and Mitral Valve Interventions in Sweden

    Dec 1, 2025, 00:00

  • CO107 Evaluating the Health Impact of Anti-PD-(L)1 Agents for Early Stage Cancer Treatment in the Czech Republic

    Dec 1, 2025, 00:00

  • EE514 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the United Arab Emirates

    Dec 1, 2025, 00:00

  • HPR32 Balancing Cost-Effectiveness With Societal Values: A Representative Survey of Norwegian Attitudes Toward Healthcare Resource Allocation

    Dec 1, 2025, 00:00

  • MSR183 ROBERTA on the Job: A Proof-of-Concept Study of a Customized GPT Tool for Risk-of-Bias Assessment of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • OP9 Gatekeepers of Scien Evolving Publishing Policies in the Age of AI

    Dec 1, 2025, 00:00

  • RWD80 Evolution of Utilization and Costs of Long-Acting Injectable Antipsychotics (LAIs) in Outpatient Care at Lisbon Psychiatric Hospital (March-May 2022 vs. 2025)

    Dec 1, 2025, 00:00

  • HSD92 Real-World Analysis of Treatment Patterns and Disease Exacerbations Among Patients Initiating Therapy for Myasthenia Gravis

    Dec 1, 2025, 00:00

  • HPR111 Harmonization of Drug Policy and Regulation Across Europe: A Comparison Between the European Medicines Agency and the European HTA Regulation

    Dec 1, 2025, 00:00

  • RWD36 Clinical Humanistic and Economic Burden Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA80 Comparator Misalignment As a Contributor to Negative Reimbursement Decisions for Pharmaceuticals in Sweden

    Dec 1, 2025, 00:00

  • MSR21 AI-Assisted Systematic Literature Screening According to NICE, UK, and CDA (Canada) Position Papers: An HTA Submission Use Case

    Dec 1, 2025, 00:00

  • MSR83 Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy

    Dec 1, 2025, 00:00

  • EE402 Economic Model of Alzheimer's Disease That Incorporates the Uncertainty Associated With Measuring Efficacy in Clinical Trials

    Dec 1, 2025, 00:00

  • SA39 Evaluating the Public Health Impact of Adolescent Meningococcal B (MenB) Vaccination in Fran A Modeling Approach

    Dec 1, 2025, 00:00

  • EE604 Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France

    Dec 1, 2025, 00:00

  • MSR58 Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study

    Dec 1, 2025, 00:00

  • HPR61 Do Health Technology Assessments (HTA) Consider Racial Health Inequalities? A Case Study of NICE HTAs for Chronic Kidney Disease Hypertension and Diabetes

    Dec 1, 2025, 00:00

  • MSR66 Dealing With Missing Data in Health Economic Studies of Small to Moderate Size: How to Minimize Bias

    Dec 1, 2025, 00:00

  • EE671 Stakeholder Engagement in the Economic Evaluation of Site-Specific Wastewater-Based Surveillance for Preventing COVID-19 Outbreaks in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • PCR192 Productivity Impacts and the Need for Carer Support in Obstructive HCM: A Patient and Carer Survey

    Dec 1, 2025, 00:00

  • EE607 Persistence to Basal Insulin and Economic Outcomes Among Patients With Type 2 Diabetes: A Retrospective Analysis Using Electronic Health Records in England

    Dec 1, 2025, 00:00

  • EE536 Impact of Maternal Vaccination Strategy on RSV-Related Hospital Burden Among Infants Aged Less Than One Year in Fran A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EE453 Expanded Access to Oncology Therapies in Mexico: The Role of Bioequivalent Abiraterone and Axitinib

    Dec 1, 2025, 00:00

  • MSR110 Flexible Parametric Inference for Cause-Specific Hazard-Competing Risk Models Under Interval Censoring

    Dec 1, 2025, 00:00

  • PCR171 Patient Involvement in Health Technology Assessment: A Global Review of Practices, Purposes, and Pathways

    Dec 1, 2025, 00:00

  • EPH109 Exploring the Impact of Socioeconomic Factors on COVID-19 Vaccine Hesitancy in India: What Can We Learn From the COVID-19 Pandemic? A Scoping Review

    Dec 1, 2025, 00:00

  • RWD145 Real-World Insights From the LOGEX IMID Observatory: A Multicountry, Multiyear Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases

    Dec 1, 2025, 00:00

  • HSD110 The Role of a Functional Clinical Staff in Guiding High-Cost Drug and Novel Technology Decision Making: Experience From a Latin American Oncology Clinic

    Dec 1, 2025, 00:00

  • EE252 Cost-Effectiveness of Genetic Testing for Optimizing Warfarin Therapy in Mechanical Heart Valve Patients: Insights From Qatar

    Dec 1, 2025, 00:00

  • HPR91 Factors Associated With Positive Cost-Effectiveness Judgments in HIRA Drug Reimbursement Decisions: An 8-year Retrospective Review

    Dec 1, 2025, 00:00

  • HPR178 Revisiting the Willingness-to-Pay Threshold in the Czech Republic: Integrating QALY Shortfall to Reflect Disease Severity and Unmet Medical Need

    Dec 1, 2025, 00:00

  • CO2 A Systematic Literature Review and Meta-Analysis Comparing Robotic-Assisted Mitral Valve Repair Using the Da Vinci Surgical System to Open Mitral Valve Repair

    Dec 1, 2025, 00:00

  • EE184 Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom

    Dec 1, 2025, 00:00

  • HPR234 Utilization of Best-Value Medicines for Teriparatide in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • EE556 Inpatient Cost of Managing Adverse Events (AEs) Associated With Immune Checkpoint Inhibitors (ICI) Approved for Advanced or Metastatic Cancers in the UK

    Dec 1, 2025, 00:00

  • HPR209 The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

    Dec 1, 2025, 00:00

  • RWD179 The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study

    Dec 1, 2025, 00:00

  • EE72 BFM 2009 (Berlin, Frankfurt, Munich) Protocol Cost Analysis for Childhood Acute Lymphoblastic Leukemia (ALL): Preliminary Real-World Data From Brazil/LATAM/LMIC

    Dec 1, 2025, 00:00

  • PT32 Can Adalimumab Serve as Big Mac Index for Pharmaceutical Prices?

    Dec 1, 2025, 00:00

  • PCR229 The Effects of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analyses

    Dec 1, 2025, 00:00

  • HTA303 Structural Uncertainty (SU) in Model-Based Economics Appraisal (MBEA): A Document Review of the French National Authority for Health (HAS)

    Dec 1, 2025, 00:00

  • RWD189 Use of Big Data to Assess Dyslipidemia Management in Gree Real-World Insights From the National Healthcare Payer

    Dec 1, 2025, 00:00

  • EPH91 Evaluate the Statistical Utility After Transformation of a CDISC SDTM Database Into OMOP CDM

    Dec 1, 2025, 00:00

  • EPH85 Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States

    Dec 1, 2025, 00:00

  • EE443 Evaluating the Economic Value of First-Line (1L) Treatment Strategies for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Insights From the Portuguese Healthcare System

    Dec 1, 2025, 00:00

  • RWD67 Disproportionality Analysis Of Vedolizumab to Identify a Putative Signal Using Real-World Postmarketing Surveillance Data Reported in the FAERS Database

    Dec 1, 2025, 00:00

  • PCR223 Taking an Equity Lens to Patient-Reported Outcomes and Experiences in Wales Using PROGRESS PLUS: A Population-Based Cross-Sectional Study

    Dec 1, 2025, 00:00

  • HPR160 Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide

    Dec 1, 2025, 00:00

  • SA30 Designing Digital Healthcare Professional Surveys: A Methodological Overview

    Dec 1, 2025, 00:00

  • HTA243 Navigating HTA and Innovation: Oncologists’ Perspectives on Access to Cancer Therapies in Bulgaria

    Dec 1, 2025, 00:00

  • PCR197 Psychometric Validation of the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ) for Mucopolysaccharidosis IVA

    Dec 1, 2025, 00:00

  • PCR180 Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies

    Dec 1, 2025, 00:00

  • HTA167 Guidelines for Health Technology Assessment Ministry of Health Sultanate of Oman

    Dec 1, 2025, 00:00

  • EE356 Economic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE91 Budget Impact Analysis of Noninvasive Tests Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Diagnosis in Japan

    Dec 1, 2025, 00:00

  • EE419 Estimating Health Utility Decrements Associated With Chronic Disease Outcomes Using MEPS

    Dec 1, 2025, 00:00

  • PT19 Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond

    Dec 1, 2025, 00:00

  • RWD33 Clinical and Economic Characteristics of eGFR-Mutated NSCLC Patients Treated With TKIs in South Korea: A Retrospective Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • HTA76 Clinical Evidence Quality in Appraisals of Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • EE652 Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025

    Dec 1, 2025, 00:00

  • RWD168 Risk of Abdominal Hernia Repair in Patients With Intestinal Stoma in Italy: A Real-World Analysis

    Dec 1, 2025, 00:00

  • MSR152 Natural History of Creutzfeldt-Jakob Disease: A Comparison of Manual vs. Manual Plus AI-Assisted Approaches in Literature Review

    Dec 1, 2025, 00:00

  • RWD5 A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Hemophilia Patients in Spain

    Dec 1, 2025, 00:00

  • HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis

    Dec 1, 2025, 00:00

  • HPR23 Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban

    Dec 1, 2025, 00:00

  • PCR191 Preferences for a Combination Influenza and COVID-19 Vaccine: Results From a Stated-Preference Survey With Consumers in the United States, United Kingdom, and Germany

    Dec 1, 2025, 00:00

  • CO193 Psychometric Evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL for Vasomotor Symptoms Caused by Endocrine Therapy: Reliability, Validity, and Differential Item Functioning

    Dec 1, 2025, 00:00

  • HTA54 Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE572 Mapping the Use of Capability Measures ICECAP-A and O in Economic Evaluations

    Dec 1, 2025, 00:00

  • RWD94 Healthcare Resource Utilization Associated With Acute Pancreatitis in Patients With Familial Chylomicronemia Syndrome Treated With Olezarsen: A Post Hoc Analysis of Balance Study Data

    Dec 1, 2025, 00:00

  • CO76 Does the Abortion Pill Harm Women? Serious Adverse Events Following Mifepristone Abortion in US Commercial and Medicaid Populations

    Dec 1, 2025, 00:00

  • RWD60 Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries’ Data Quality

    Dec 1, 2025, 00:00

  • EPH141 Incidence and Treatment of Squamous-Cell Anal Cancer (SCAC) in Germany: A Retrospective Study in German Statutory Health Insurance (SHI) Claims Data

    Dec 1, 2025, 00:00

  • HTA372 Will Patient Input Shape EU-Level HTA Assessments? HTA Representative Perspectives on the EU HTA Regulation

    Dec 1, 2025, 00:00

  • CO86 Effectiveness of Pneumococcal Vaccines in Preventing Otitis Media in Children: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA219 Level of ICER of Health Economic Assessment in France in 2024

    Dec 1, 2025, 00:00

  • HPR50 Comparison of Alignment Between EMA Indications and National Reimbursement Decisions in Italy for Orphan Drugs

    Dec 1, 2025, 00:00

  • EE302 Cost-Utility Analysis of Iptacopan for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With C5 Inhibitor in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EPH183 Postherpetic Neuralgia Occurrence and Herpes Zoster Recurrence in Immunocompromised Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study (Clinical Practice Research Datalink 2012-2019)

    Dec 1, 2025, 00:00

  • MT5 Artificial Intelligence in Health Economics: Opportunities and Challenges for the Future: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE550 Increased Healthcare Resource Utilization Among Uncontrolled vs. Controlled Hypertension Population: Findings From the EnligHTN Study

    Dec 1, 2025, 00:00

  • EE23 A Model-Based Estimation of Productivity-Adjusted Life Years Due to Depression in Germany

    Dec 1, 2025, 00:00

  • EE567 Live Attenuated Influenza Vaccination (LAIV) for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EPH92 Evaluating Performance of the Experimental EQ-TIPS (V3) for Assessing Infants and Toddlers With Acute Infections: A Mixed-Methods Approach of Cognitive Debriefing and Psychometric Testing

    Dec 1, 2025, 00:00

  • HTA155 From License to Reimbursement: A Slot-Based ML Framework for Seamless MA to HTA Alignment

    Dec 1, 2025, 00:00

  • EE540 Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain

    Dec 1, 2025, 00:00

  • EE127 Clinical and Economic Benefits of Extended-Release Metformin In Prediabetes Management

    Dec 1, 2025, 00:00

  • EPH94 Evaluation of Participation Data in the Context of Cancer Prevention

    Dec 1, 2025, 00:00

  • CO75 Disease Progression Modeling for an Ultra-Rare Disease: Lysosomal Acid Lipase Deficiency (LAL-D)

    Dec 1, 2025, 00:00

  • MSR201 The Role of Qualitative Research in Randomized Controlled Trials Involving Drugs and Medical Devices: A Systematic Mapping Review

    Dec 1, 2025, 00:00

  • HSD76 Modeling the Environmental and Cost Impact of a Novel Detergent in NHS Endoscope Reprocessing Workflows

    Dec 1, 2025, 00:00

  • EE458 Exploring the Economic Burden Associated With Chronic Obstructive Pulmonary Disease (COPD) Due to Alpha1 Antitrypsin Deficiency (AATD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HPR4 A Comparative Analysis of Regulatory Divergence in Expedited Oncology Approvals: Evidence, Pathways, and Timelines Across FDA, EMA, TGA, and PMDA

    Dec 1, 2025, 00:00

  • EPH158 Literature Review on the Economic Impact of Maternal Fetal Infections

    Dec 1, 2025, 00:00

  • MSR139 Long-Term Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Investigating a Parametric Survival Model for Extrapolations

    Dec 1, 2025, 00:00

  • PCR134 Impacts of Patient-Centered Collaboration: Application of a Continuous Engagement Plan Across Multiple Phases of the Insights and Patient Experiences With Cardiovascular Disease (IPEC) Initiative

    Dec 1, 2025, 00:00

  • HPR168 Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape

    Dec 1, 2025, 00:00

  • MSR144 Measuring Health-Related Quality of Life and Food Insecurity in the General Population in Lebanon During the Third Worst Socioeconomic Crisis in History

    Dec 1, 2025, 00:00

  • EE332 Direct Economic Impact of Idiopathic Pulmonary Fibrosis on the Brazilian Private Healthcare System: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • EE747 Value-Based Assessment of Trifluridine Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Dec 1, 2025, 00:00

  • CO236 The Clinical Burden and Complications Associated With Glycogen Storage Disease Type Ia (GSDIa): Results From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE188 Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in ...

    Dec 1, 2025, 00:00

  • CO213 Review of Index Line Selection Methods in Hemato-Oncology Externally Controlled Trials: A Secondary Analysis of the Hermans et al Systematic Review

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • HPR240 Who Pays the Price? International Impacts of US Drug-Cost Benchmarking

    Dec 1, 2025, 00:00

  • CO151 Indirect Treatment Comparisons in Health Technology Assessment Submissions: A Review and Critique of Best Practice

    Dec 1, 2025, 00:00

  • EPH188 Prevalence and Overlap of Overweight/Obesity Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease in England: A Clinical Practice Research Datalink Study

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • HTA3 A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany

    Dec 1, 2025, 00:00

  • EE148 Components of the Direct Cost of Topical Treatment for Chronic Wounds in Adults and Elderly: A Systematic Review

    Dec 1, 2025, 00:00

  • EE75 Bimekizumab’s Synergistic Economic Impact Across Four Indications in France

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • HTA185 HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals

    Dec 1, 2025, 00:00

  • EE255 Cost-Effectiveness of I-CREATE: An Inpatient Intrinsic Capacity Risk Evaluation Towards Holistic Assessment and Targeted Management of Elderly in Acute Care

    Dec 1, 2025, 00:00

  • PCR225 The Burden of Cognitive Impairment Associated With Schizophrenia (CIAS) on People With Lived Experience (PWLE): A National Canadian Survey

    Dec 1, 2025, 00:00

  • HTA350 Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies

    Dec 1, 2025, 00:00

  • SA49 Health-Related Quality of Life Impacts of Living With Primary Lateral Sclerosis (PLS): The Development of a Conceptual Model

    Dec 1, 2025, 00:00

  • EE232 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan

    Dec 1, 2025, 00:00

  • EE49 An Interactive R-Shiny Application for Budget Impact Modeling of Cell and Gene Therapies With Multiple Innovative Payment Scenarios

    Dec 1, 2025, 00:00

  • EE19 A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire

    Dec 1, 2025, 00:00

  • EE130 Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High-Efficacy Disease-Modifying Therapy in Mexico

    Dec 1, 2025, 00:00

  • EE173 Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective

    Dec 1, 2025, 00:00

  • HTA97 Cost-Effectiveness Modeling Challenges and Trends in the Neoadjuvant and Perioperative Settings: A Review of NICE Oncology Submissions

    Dec 1, 2025, 00:00

  • EE377 Economic Evaluation of Cefiderocol for the Treatment of Confirmed MBL-Producing Pathogens in Italy

    Dec 1, 2025, 00:00

  • HPR65 Early Access Programs and Pricing and Reimbursement Agreements in Portugal for Orphan Medicines Centrally Approved in the European Union

    Dec 1, 2025, 00:00

  • HTA109 Development of a Unique Tool for Assessing the Feasibility of an External Control Arm Study

    Dec 1, 2025, 00:00

  • PCR208 Registry Participation in Rare Diseases: Insights from Stakeholders and an Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)

    Dec 1, 2025, 00:00

  • SA70 Modeling the Lifetime Effects of Lecanemab in Early Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • P35 Incorporating Environmental Impacts Into Budget Impact Models: A Case Study of CAR-T Therapies in France

    Dec 1, 2025, 00:00

  • EE647 Relationship Between Cost-Effectiveness Threshold and Drug Reimbursement in Spain, Italy, and France

    Dec 1, 2025, 00:00

  • MSR11 Accounting for Cure Rates Estimated from Progression-Free Survival (PFS) in Long-Term Overall Survival (OS) Projections: A Case Study from Previously Treated Advanced Cancers

    Dec 1, 2025, 00:00

  • EE172 Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis

    Dec 1, 2025, 00:00

  • EE367 Economic Burden of the Adverse Events During Treatment of Metastatic Breast Cancer (mBC) HR(+) HER2(-) Patients in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • HTA141 Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions

    Dec 1, 2025, 00:00

  • CO82 Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study

    Dec 1, 2025, 00:00

  • HTA90 Consideration of Off-Label Therapies as Appropriate Comparator Therapy in Early Benefit Assessments in Germany Under the ALBVVG Legislation

    Dec 1, 2025, 00:00

  • HTA26 Advancing Patient Involvement in Health Technology Assessment

    Dec 1, 2025, 00:00

  • RWD84 Feasibility Assessment of Real-World Data for Trial Emulations: A Methodological Framework

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • PCR31 Bimekizumab Demonstrated Sustained Long-Term Improvements in Health-Related Quality of Life and Work Productivity in Patients With Active Psoriatic Arthritis: 3-Year Results from Two Phase 3 Studies

    Dec 1, 2025, 00:00

  • EE65 Assessing Time Tradeoff Utilities in Health States of Organic Hypogonadotropic Hypogonadism: A Pilot Study in Brazil

    Dec 1, 2025, 00:00

  • EPH8 A Retrospective Study of Treatment Use in Metastatic Colorectal Cancer (mCRC) Based on French Hospital Discharge Database

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • MSR134 Interpreting PRO-CTCAE Data: Defining and Answering the Right Questions

    Dec 1, 2025, 00:00

  • HTA14 A Review of NICE Technology Appraisals in Oncology Including Economic Evaluations With Time-Varying Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EE661 Societal and Economic Impact of Targeted Therapy for Breast Cancer in Bulgaria

    Dec 1, 2025, 00:00

  • HPR86 Exploring Off-Label Drug Coding Trends in French Hospitals: A Descriptive and Stratified Analysis 2020-2024

    Dec 1, 2025, 00:00

  • RWD152 Real-World Evidence From Community Oncology: Assessing Secular Trends in Ovarian Cancer Diagnoses From 2014 to 2024

    Dec 1, 2025, 00:00

  • HPR212 Extent and Causes of the Collapse in the Registration of Innovative Medications in Lebanon: A Mixed-Methods Analysis

    Dec 1, 2025, 00:00

  • HPR228 Understanding the Impact of Cost-Effectiveness Evaluations on Drug Pricing in Japan: A Case Study of Oncology Therapies

    Dec 1, 2025, 00:00

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • PCR147 Is There a Lack of Dietary Data Collection in Real-World IBD Studies? Literature Review and Future Considerations

    Dec 1, 2025, 00:00

  • CO152 Inefficiencies of Off-Label Therapy in the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Real-World Evidence From Europe

    Dec 1, 2025, 00:00

  • P47 Quality of Life and Utility Values Across the Alzheimer’s Disease Spectrum: Results From the What Matters Most Survey

    Dec 1, 2025, 00:00

  • RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

    Dec 1, 2025, 00:00

  • P26 Approximating Competing Risk Events From Published Kaplan-Meier Curves Using Simultaneity-Based Event Assignment Methods

    Dec 1, 2025, 00:00

  • EE610 Population Impact of Performing BRCA1/2 Testing to Guide Metastatic Castration-Resistant Prostate Cancer Treatment in Spain

    Dec 1, 2025, 00:00

  • EE215 Cost-Effectiveness Analysis of Pediatric and Adult Pneumococcal Conjugate Vaccine Strategies in Canada

    Dec 1, 2025, 00:00

  • HPR138 Market Access Challenges for Oncology Combination Therapies in Europe: A Review of Regulatory Approvals HTA Outcomes and Pricing Dynamics

    Dec 1, 2025, 00:00

  • PCR101 Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA373 Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies

    Dec 1, 2025, 00:00

  • CO191 Prognostic Factor Evaluation for Clinical Outcomes in HER2-Mutant NSCLC

    Dec 1, 2025, 00:00

  • EE131 Clinical and Economic Impact of Hospital-Acquired Infections by Pseudomonas Aeruginosa in a Tertiary Care Teaching Hospital in India

    Dec 1, 2025, 00:00

  • HPR47 Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and Fran Lessons for Poland

    Dec 1, 2025, 00:00

  • EE219 Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal

    Dec 1, 2025, 00:00

  • EE42 The Value of Investing in Innovative Medicines: A Scalable Approach to Measure the Lifetime Social Impact

    Dec 1, 2025, 00:00

  • HTA317 The Growing Role of Real-World Evidence (RWE) to Support Efficacy in EMA Oncology Approvals: Light at the End of the Tunnel

    Dec 1, 2025, 00:00

  • HTA222 Life-Years Lost Due to Regulatory and Reimbursement Delays: A Study of Oncology Drugs Across England, Scotland, and France, 2022-2024

    Dec 1, 2025, 00:00

  • MSR174 Psychometric Evaluation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire Item-10 (Physical Fatigue) and Idiopathic Thrombocytopenic Purpura Bleeding Scale Using LUNA 3 Phase 3 Trial Data

    Dec 1, 2025, 00:00

  • PCR100 From Pain to Patient Preferences Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • CO176 Pain-Related Disparities in Healthcare Expenditures Among Individuals With Cancer Evidence From the United States Medical Expenditure Panel Survey

    Dec 1, 2025, 00:00

  • CO16 Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe

    Dec 1, 2025, 00:00

  • HPR229 Unintended Consequences of MFN Pricing: Global Access Risks and Revenue Impact

    Dec 1, 2025, 00:00

  • SA4 A Systematic Literature Review of Prognostic Factors in Advanced Merkel Cell Carcinoma

    Dec 1, 2025, 00:00

  • EE655 Saving Money Improving Outcomes: A Two-Year Cost-Utility Analysis of Emergency Department Care Models for Managing Persons Presenting With a Musculoskeletal Disorder

    Dec 1, 2025, 00:00

  • HTA158 From Theory to Practi Guidance for Identifying and Selecting Mapping Algorithms for Health Economic Models

    Dec 1, 2025, 00:00

  • HPR142 Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe

    Dec 1, 2025, 00:00

  • RWD140 Real-World Effectiveness of Immune Checkpoint Inhibitors Chemotherapy (ICI+CT) vs. ICI Monotherapy (ICI) in Untreated Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE602 Optimizing Therapeutic Strategies for Multiple Sclerosis in Italy: A Budget Impact Analysis

    Dec 1, 2025, 00:00

  • HPR172 Registration and Access to Orphan Medicines in Türkiye: A Comparative Study With Poland and Germany

    Dec 1, 2025, 00:00

  • HTA71 Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise

    Dec 1, 2025, 00:00

  • EE476 Forecasting the Rise in Direct and Indirect Costs for Lung Cancer on the Example of Poland

    Dec 1, 2025, 00:00

  • RWD106 Influencing Factors on the Health-Related Quality of Life of Middle-Aged and Elderly People in Ethnic Minority Areas of China: An Analysis Based on the Survey in a Urban Community of Guangxi Province

    Dec 1, 2025, 00:00

  • HSD35 Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy

    Dec 1, 2025, 00:00

  • RWD22 Assessment of Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland

    Dec 1, 2025, 00:00

  • EE700 The Economic Burden of Inflammatory Arthritis: A Systematic Review

    Dec 1, 2025, 00:00

  • EE379 Economic Evaluation of Dinutuximab Beta in the Maintenance Therapy of High-Risk Neuroblastoma in Brazil

    Dec 1, 2025, 00:00

  • EPH95 Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024)

    Dec 1, 2025, 00:00

  • EPH220 Studying Paternal Drug Exposures and Offspring Outcomes: A Feasibility Assessment of 11 Large European Databases

    Dec 1, 2025, 00:00

  • EPH163 Modeling the Public Health Impact of Nirsevimab and Maternal Vaccination With RSVpreF Against Infant Respiratory Syncytial Virus Infection in Germany

    Dec 1, 2025, 00:00

  • PCR66 Domain Attrition in the IWQOL Series and the Challenges of Factor-Only Item Reduction

    Dec 1, 2025, 00:00

  • SA101 Using a Large Language Model (LLM) for Data Extraction of Studies: Learnings From a Targeted Literature Review (TLR) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • HSD52 From Agricultural Waste to Clinical Value: An Economic and Operational Analysis of Paddy Straw-Based Utensils in Malaysian Hospital

    Dec 1, 2025, 00:00

  • EE338 Do Public Preferences Matter? Health-Economic Evaluation of Antineoplastic Medication Considering EQ-5D Value Sets From Several Countries

    Dec 1, 2025, 00:00

  • EE118 Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study

    Dec 1, 2025, 00:00

  • CO254 Treatment Response in Pediatric Patients With Status Epilepticus: A Retrospective Observational Study From Saudi Arabia

    Dec 1, 2025, 00:00

  • HTA52 Barriers to Reimbursement: Characteristics of Unfunded Medicines in Ireland (2006-2021)

    Dec 1, 2025, 00:00

  • HTA293 Role of Real-World Evidence (RWE) in Pricing and Reimbursement Decisions for Rare Disease in Health Technology Assessment (HTA) Submissions Across EU4 + UK

    Dec 1, 2025, 00:00

  • HTA265 Patient Access Delays in Multi-Indication Medicines: A Review of Health Technology Assessment Timelines

    Dec 1, 2025, 00:00

  • EPH264 Trends in the Number of Hospital Beds and Patient Turnover in Obstetrics and Gynecology in Hungary Between 2003 and 2023

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • P24 A Framework for Accelerating Clinical Development With Real-World External Control Arms (ECA) in Phase 2 Trials

    Dec 1, 2025, 00:00

  • HPR180 Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care

    Dec 1, 2025, 00:00

  • EE487 Health Economic Analysis of Malnutrition in the Netherlands

    Dec 1, 2025, 00:00

  • HTA49 Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • CO11 Antibody-Drug Conjugates in Colorectal Cancer: A Scoping Review of Current Evidence and Emerging Clinical Trends

    Dec 1, 2025, 00:00

  • EE464 Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis

    Dec 1, 2025, 00:00

  • P8 Assessing the Full Life-Cycle Value of Highly Specialized Technologies and Advanced Therapy Medicinal Products in England

    Dec 1, 2025, 00:00

  • EE520 How Can Intravitreal Aflibercept 8 mg Impact Treatment Burden and Costs in European Patients With Diabetic Macular Edema? From Clinical Trials to Clinical Practice

    Dec 1, 2025, 00:00

  • HPR109 Global Pricing Meets Domestic Policy: Analyzing the Financial Impact of the Most-Favored Nation Approach on the United States Medicine Prices

    Dec 1, 2025, 00:00

  • EE526 Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study

    Dec 1, 2025, 00:00

  • MSR171 Prediction of Query Outcomes in the Setting of Observational Studies

    Dec 1, 2025, 00:00

  • EE503 Healthcare Resource Use Among Patients With Chronic Rhinosinusitis With Nasal Polyps in the United Kingdom: Results of an Expert Elicitation Survey

    Dec 1, 2025, 00:00

  • HTA269 Paving the Path to Success for Joint Clinical Assessments: One Asset at a Time

    Dec 1, 2025, 00:00

  • SA83 Real-World Utilization Patterns of Corticosteroids in Ulcerative Colitis: Prevalence of Excessive Use in Routine Clinical Practice

    Dec 1, 2025, 00:00

  • HTA282 Recognizing the Full Value of Novel Antibiotics: Identifying Value Elements in the Context of Antimicrobial Resistance

    Dec 1, 2025, 00:00

  • Methodological Challenges With Conducting Health Economic Evaluations in the Critical-Care Context

    Dec 1, 2025, 00:00

  • EPH255 The Role of Lifestyle in the Development of Fertility Issues

    Dec 1, 2025, 00:00

  • HPR128 International Reference Pricing (IRP) Analysis for Original Medicines in Türkiye in 2024

    Dec 1, 2025, 00:00

  • MSR81 Effect of Positive Airway Pressure Therapy on Mortality in European Obstructive Sleep Apnea Patients: Post Hoc Analysis of a Global Meta-Analysis

    Dec 1, 2025, 00:00

  • EE146 Comparative Analysis of Different Crown Materials for Dental Prosthesis From Budget in Wartime in Ukraine

    Dec 1, 2025, 00:00

  • CO257 Understanding XLH’s Impact: Incorporating Patient Perspectives to Develop a Comprehensive Conceptual Disease Model (CDM) to Drive Patient Engagement and the Generation of Meaningful Patient Experience Data

    Dec 1, 2025, 00:00

  • RWD137 Prevalence Utilization Patterns and Economic Impact of eGFR and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Real-World Analysis From Greece

    Dec 1, 2025, 00:00

  • PT7 The Association Between Average Sales Price Decline and Shortages in Small Molecule Injectable Oncology Therapies With Generic Competition

    Dec 1, 2025, 00:00

  • EPH19 Artificial Intelligence in Evidence Synthesis: A Systematic Review and Meta-Analysis of Emerging Biologics for Improving Skeletal Health in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • EPH276 Utility Values for Dementia in Finland and Spain

    Dec 1, 2025, 00:00

  • MSR203 Traditional vs. Generative AI: A Rapid Systematic Review Assessing Accuracy and Efficiency of AI in Title/Abstract Screening

    Dec 1, 2025, 00:00

  • HPR39 Budget Impact of Anakinra in Turkiye: An Analysis From the Social Security Institution’s Perspective

    Dec 1, 2025, 00:00

  • EE585 Modeling the Clinical and Economic Impact of DPP-4 Inhibitors in Uncontrolled T2D

    Dec 1, 2025, 00:00

  • PCR173 Patient Perspectives on Disease Experiences and Value of Real-Time Self-Reported Symptom and Treatment Monitoring in Locally Advanced and Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • HPR122 Including Decision Uncertainty About the Clinically Minimal Important Differen Shifting From Risk Aversion to Risk Awareness in Drug Reimbursement Processes

    Dec 1, 2025, 00:00

  • EPH195 Psychotropic Medications to Patients With Treatment-Resistant Depression in France

    Dec 1, 2025, 00:00

  • EE46 An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt

    Dec 1, 2025, 00:00

  • EE254 Cost-Effectiveness of High-Dose vs. Adjuvanted Trivalent Influenza Vaccines in Older Adults in Korea

    Dec 1, 2025, 00:00

  • MSR15 Advancing Target Trial Emulation With Synthetic Data: The Target Trial Optimization Framework

    Dec 1, 2025, 00:00

  • HSD46 Evaluating the Digital Transformation in Healthcare: Adoption, Challenges, and Opportunities

    Dec 1, 2025, 00:00

  • EE317 Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Gree A Cost Utility Analysis

    Dec 1, 2025, 00:00

  • P10 Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities From a Targeted Literature Review and Multi-Stakeholder Workshop

    Dec 1, 2025, 00:00

  • PCR231 The Impact of Inhaler Technique on the Health Outcomes and Cost Among Adults With Asthma and Chronic Obstructive Pulmonary Disease in Saudi Arabia

    Dec 1, 2025, 00:00

  • RWD162 Real-World Patient Characteristics and Outcomes Associated With Antibody Drug Conjugate Therapy: A Large Cohort Study

    Dec 1, 2025, 00:00

  • P61 Utilizing LLMs to Enhance Patient-Reported Outcome Measures: Application to the EQ-5D and Bolt-ons

    Dec 1, 2025, 00:00

  • EE244 Cost-Effectiveness of Delgocitinib vs. PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema

    Dec 1, 2025, 00:00

  • SA64 Mapping Disease-Specific Patient-Reported Outcome Measures (PROMs) to EQ-5D Utility Scores: A Systematic Review

    Dec 1, 2025, 00:00

  • EE478 Foregone Net Monetary Benefit From Underdiagnosis and Undertreatment of Mild Cognitive Impairment Due to Alzheimer’s Disease in the Medicare Population

    Dec 1, 2025, 00:00

  • SA84 Screening and Diagnosis of Paroxysmal Nocturnal Hemoglobinuria in Gree Consensus Recommendations From a Multispecialty Expert Panel

    Dec 1, 2025, 00:00

  • PCR78 Establishing the Relationship Between the Worst Itch Numerical Rating Scale and EQ-5D Utility in Patients With Primary Biliary Cholangitis Experiencing Pruritus: Pooled Results From GLIMMER and the PRO Validation Study

    Dec 1, 2025, 00:00

  • EE507 Healthcare Resource Utilization in Patients With Hidradenitis Suppurativa Using Adelphi Real-World Data From EU5 and US

    Dec 1, 2025, 00:00

  • EE398 Economic Impact of Faricimab in Neovascular Age-Related Macular Degeneration Management in France

    Dec 1, 2025, 00:00

  • EE222 Cost-Effectiveness and Budget Impact Analysis of Noninvasive Prenatal Testing (NIPT) for the Identification of Fetal Chromosomal Aneuploidies in Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • PCR252 Triangulation Method to Detect Meaningful Deterioration in Patient's Autonomy Using the New Multiple Sclerosis Autonomy Scale (MSAS) Questionnaire

    Dec 1, 2025, 00:00

  • EE560 Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models

    Dec 1, 2025, 00:00

  • HPR2 A Case Study: How England Implemented Its First Population Health Agreement

    Dec 1, 2025, 00:00

  • EE434 Evaluating the Budget Impact of Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) in Patients With Moderate to Severe Asthma in the Saudi Healthcare System

    Dec 1, 2025, 00:00

  • EPH41 Characteristics Associated With Having an Activity of Daily Living Limitation (ADLL) or Instrumental Activity of Daily Living Limitation (IADLL) Among US Adults With Asthma

    Dec 1, 2025, 00:00

  • Cost-Effectiveness of Interventions Addressing Loneliness Among Adults: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR148 Navigating Three Systems: A Comparative Analysis of Pharmaceutical Reimbursement in Germany, Austria, and Switzerland

    Dec 1, 2025, 00:00

  • CO110 Evaluating the Repurposing Potential of Statins: Association Between Statin Use and Cognitive Decline in Patients With Mild-to-Moderate Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • PCR128 Impact of Cancer on the Burden of Caregiving in China, Japan, and EU5: National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • EE573 Markov Model-Based Cost-Effectiveness Evaluation of ROSA® vs. Manual Total Knee Arthroplasty: Sweden Payer Perspective

    Dec 1, 2025, 00:00

  • HPR235 Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System

    Dec 1, 2025, 00:00

  • HTA249 Navigating the Transition: What EU JCA Means for AMNOG Submissions in 2025 and Beyond

    Dec 1, 2025, 00:00

  • HSD72 Mapping the Landscape of Digital Healthcare Services Delivered by Specialized Oncology Hospitals in China: Qualitative Analytical Study

    Dec 1, 2025, 00:00

  • EE440 Evaluating the Economic Benefit of Improved High-Dose Influenza Vaccine Coverage in the Elderly Population of Tokyo, Japan

    Dec 1, 2025, 00:00

  • PCR235 The Life With Amyotrophic Lateral Sclerosis: Socioeconomic Impact of the Disease on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2025, 00:00

  • EE665 Socioeconomic and Geographic Inequalities in Colorectal Cancer Care Utilization and Expenditures: A Decomposition Analysis

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »